| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| HAN YOU FINANCIAL MANAGEMENT MANAGEMENT CONSULTANT CO., LTD. | Chairman | 1.16% | |
| Zhong,Xin-Yong | Director | 2.33% | SFS VENTURE LTD. |
| Chen,Zheng | Director | 2.33% | SFS VENTURE LTD. |
| Chen,Yong-Fa | Director | 1.96% | MIN JU INVESTMENT CO., LTD. |
| Xie,Rong-Sheng | Director | 1.96% | MIN JU INVESTMENT CO., LTD. |
| JIA JU INVESTMENT LTD. | Director | 1.38% | |
| Zhang,Ri-Yan | Independent Director | 0.09% | |
| Lin,Zhi-Ming | Independent Director | 0.00% | |
| Zheng,Qin-Hua | Independent Director | 0.00% |
Change Company Name to Savior Lifetec Corporation
2023/11/28
Change Company Name to SONGRUI PHARMACEUTICAL CO., LTD. (FORMER NAME: ZHANWANG LIFE TECHNOLOGY CO., LTD.)
2022/06/13
Change Company Name to Savior Lifetec Corporation
2020/06/23
Change Capital to 3,500,000,000
2019/07/23
Change Capital to 2,500,000,000
2015/06/01
Change Person in Charge to Han You,Cai-Wu-Guan-Li-Gu-Wen-Gu-Fen-You-Xian-Gong-Si
2014/06/13
Change Capital to 1,800,000,000
2013/01/07
Change Capital to 1,500,000,000
2011/05/16
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 263,861 | 1,217,327 | 1,050,277 |
| Operating cost | 166,605 | 870,571 | 829,328 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 97,256 | 346,756 | 220,949 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 97,256 | 346,756 | 220,949 |
| Operating expenses | 70,492 | 227,856 | 223,369 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 26,764 | 118,900 | -2,420 |
| Non-operating income and expenses | 358,364 | 60,501 | 29,959 |
| Net profit (loss) before tax | 385,128 | 179,401 | 27,539 |
| Income tax expense (benefits) | - | 991 | 42 |
| Net profit (loss) of ongoing business for the current period | 385,128 | 178,410 | 27,497 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 385,128 | 178,410 | 27,497 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 385,128 | 178,410 | 27,497 |
| Net profit (loss) attributable to owners of parent company | 386,076 | 182,380 | 30,030 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -948 | -3,970 | -2,533 |
| Comprehensive profit (loss) attributable to owners of parent company | 386,076 | 182,380 | 30,030 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -948 | -3,970 | -2,533 |
| Basic earnings per share (yuan) | 1 | 0 | 0 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 25,557 | 518,378 | 387,952 |
| Net cash inflows (outflows) from investing activities | 162,175 | -203,494 | 181,190 |
| Net cash inflow (outflow) from financing activities | -2,934 | -39,740 | -572,216 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | 184,798 | 275,144 | -3,074 |
| Beginning balance of cash and cash equivalents | 1,358,063 | 1,082,919 | 1,085,993 |
| Ending balance of cash and cash equivalents | 1,542,861 | 1,358,063 | 1,082,919 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 3,085,247 | 3,249,209 | 2,546,210 |
| Non-current asset | 1,158,134 | 1,126,911 | 1,276,461 |
| Total asset | 4,243,381 | 4,376,120 | 3,822,671 |
| Current liability | 171,762 | 690,439 | 200,918 |
| Non-current liability | 170,394 | 169,584 | 257,039 |
| Total liability | 342,156 | 860,023 | 457,957 |
| share capital | 3,173,991 | 3,173,991 | 3,173,991 |
| Equity - secruity token | - | - | - |
| capital reserve | 135,127 | 135,127 | 135,127 |
| retained earning | 585,053 | 198,977 | 43,624 |
| Other equity | - | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 3,894,171 | 3,508,095 | 3,352,742 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 7,054 | 8,002 | 11,972 |
| Total Equity | 3,901,225 | 3,516,097 | 3,364,714 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 12 | 11 | 10 |
| 日期 | 違反法規法條 | 罰鍰金額 |
|---|---|---|
| 2022/09/05 | Paragraph 4, Article 38 of the Labor Standards Act | 20,000 |
| 2022/07/05 | Paragraph 2, Article 22 of the Labor Standards Act | 20,000 |
| 2022/05/23 | Article 43 of the Labor Standards Act | 20,000 |
| 2022/05/10 | Paragraph 4, Article 38 of the Labor Standards Act | 20,000 |
| 2022/05/03 | Paragraph 1, Article 6 of the Occupational Safety and Health Act | |
| 2021/05/13 | Paragraph 1, Article 6 of the Occupational Safety and Health Act |
